

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Christina Lake Cannabis Corp. (the “Issuer”).

Trading Symbol: CLC

Number of Outstanding Listed Securities: 99,352,315 common shares were issued and outstanding as of December 31, 2020

Date: January 7, 2021 (for the month of December, 2020)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a premier producer of high quality, low cost, sun-grown cannabis flower, oil cannabinoids and hemp-based extracts and derivatives, serving domestic and international markets.

2. Provide a general overview and discussion of the activities of management.

During the month of December 2020, management's principal activities consisted of:

- closing a non-brokered private placement of 5,540,000 units at a price of \$0.30 per unit for gross proceeds of \$1,662,000;
- closing a shares for services agreement and issuing 300,000 common shares as partial payment for 2,000 yards of soil.
- successfully completing its inaugural harvest from the 2020 growing season which exceeded production targets by over 44%, leading to plans to expand its grow operations in 2021 to capitalize on the several unique advantages that can be had by growing cannabis outdoors in Christina Lake, BC;
- appointing Gil Playford, an internationally accomplished senior corporate executive and entrepreneur in the mining and resource sectors, to its Board of Directors as well as to the Chairman position of its audit committee and finance committee;
- producing its first batch of cannabis-derived crude oil produced using its Vitalis R-200-H-GMP-SS extraction system, which was commissioned earlier in the quarter; and
- general management and administrative matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of December 2020, the Issuer announced that it has produced its first batch of cannabis-derived crude oil produced using its Vitalis R-200-H-GMP-SS extraction system ("Vitalis System". Within weeks of commissioning the Vitalis System, over 300 kg / 660 lb of crude oil has been produced. The Issuer's

objective is to provide a consistent supply of distillate and full-spectrum oils with terpenes derived from unique strains of cannabis grown outdoors by sunlight.

The Issuer also has accumulated a genetic databank with a portfolio of more than 100 proprietary cannabis strains specifically formulated for growing outdoors under sunlight. The Issuer has undertaken extensive R&D work to develop over 100 strains in-house with an objective of maximizing output from its growing activities. The Issuer currently holds a total inventory of more than 600,000 seeds, from which a selection is to be used for the 2021 growing season

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of December 2020.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

During the month of December, the Issuer entered into a purchase agreement with an arm's length party whereby the Issuer agreed to issue 300,000 common shares at a price of \$0.48 per share for the partial payment of 2,000 yards of soil.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties that terminated or expired and there weren't any previously announced financing arrangements that terminated during the month of December 2020.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or disposition of the Issuer's assets during the preceding month of November 2020.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisitions of new customers or loss of customers during the month of December 2020.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of December 2020.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of December 2020.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of December 2020.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of December 2020.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of December 2020.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Units, comprised of one common share and one half of one common share	5,540,000	Private placement of Units at a price of \$0.30 per Unit	Proceeds received from the private placement will be used for marketing, development of its products, investor relations activity,

Security	Number Issued	Details of Issuance	Use of Proceeds
purchase warrant			and for general working capital purposes.
Common shares	300,000	Issued pursuant to a purchase agreement for partial payment of soil at a deemed price of \$0.48 per share	N/A
Common Shares	449,500	Exercise of various stock options	Proceeds received from the exercise of stock options will be used for general working capital.
Common Shares	2,622,500	Exercise of various warrants	Proceeds received from the exercise of stock options will be used for general working capital.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons of the Issuer during the month of December 2020.

16. Provide details of any changes in directors, officers or committee members.

As at the date of this report, the directors and officers of the Issuer are as follows:

Mervin Boychuk	Director and Non-Executive Chairman, Chairman of compensation committee
Nicco Dehaan	Director, Chief Operating Officer and a Member of the Audit Committee
Joel Dumaresq	Director and Chief Executive Officer, member of compensation committee
Tim O'Donnell	Corporate Secretary
Gil Playford	Director, Chairman of the Audit Committee, member of compensation committee
Ryan Smith	Chief Financial Officer
Jason Taylor	Director and a Member of the Audit Committee

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the period ended August 31, 2020 dated as of October 30, 2020 under the headings "FINANCIAL INSTRUMENTS AND RISKS" and "RISK FACTORS". The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

In addition to the trends and risks detailed in the MD&A, COVID-19 is likely to impact the Issuer:

COVID-19

The outbreak of the corona virus pandemic has impacted the Issuer's plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 7, 2021.

Joel Dumaresq
Name of Director or Senior
Officer

"Joel Dumaresq"
Signature

Chief Executive Officer
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YY/MM/D
Christina Lake Cannabis Corp.	December 2020	2021/01/07
Issuer Address		
Suite 810 – 789 West Pender Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 1H2	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Joel Dumaresq	CEO	(604) 336-3193
Contact Email Address	Web Site Address	
info@partumadvisory.com	www.christinalakecannabis.com	